Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Parkinson's Disease (PD) is a major neurodegenerative disorder in which there is a
progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of
dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a
precursor of DA that crosses the blood brain barrier, and also to the use of selective
inhibitors of MAO-B, the major DA metabolising enzyme in humans.
Safinamide is an inhibitor of MAO-B. This study is to evaluate the long term safety and
tolerability of safinamide in PD patients, that have already completed a previous clinical
study with Safinamide. The physical and neurological conditions as well as other safety
parameters will get compared from baseline to subsequent visits.